View profile

FarmaKology Newsletter - Issue #37

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


March 11 · Issue #37 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+3300 Subscribers ) !

Today's Startup
Tracworx, a valuable and infrastructure free perioperative care solution that combines equity, equality and efficiency through intelligent predictive analytics.Tracworx is a patient centric platform for perioperative care teams focusing on providing a seamless patient journey pre, during and post operation which is set to revolutionise surgery management.The platform is an intelligent wearable device that provides insights using both patient and equipment locations throughout the whole perioperative journey. When this information is correlated with specific data to each individual case, it identifies trends and records key performance indicators of a theatre.
CEL-SCI Corporation  announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties.
The US Food and Drug Administration (FDA) and Federal Trade Commission (FTC) have issued warning letters to seven companies for selling fraudulent COVID-19 products that claim to treat or prevent the virus. At current there is no approved prevention or therapy for coronavirus.According to the agencies, the products being sold are unapproved and pose a significant risk to patient health, as they may be unsafe for consumption and/or stop or delay patients getting necessary medical diagnoses and treatments.
The European Medicine Agency (EMA) has organised the first meeting of an executive steering group, which will address the potential impact of the novel coronavirus on the medicine supply chain in the European Union.In a statement issued this morning, the EMA said that it is already working with partners in the European medicines regulatory network to monitor the impact of the novel coronavirus – which causes the respiratory illness known as COVID-19 – on pharmaceutical supply chains in the EU.
Angelini Pharma announces today it has acquired the ThermaCare® global business rights, excluding North America, from GSK. The deal also includes the dedicated US manufacturing site for ThermaCare in Albany, Georgia.
Research & Study
Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China by STAT | Free Listening on SoundCloud
Job Opportunities
Upcoming Events
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue